Disc Medicine
IRON
62 hedge funds and large institutions have $93.8M invested in Disc Medicine in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 18 reducing their positions, and 13 closing their positions.
246% more call options, than puts
Call options by funds: $211K | Put options by funds: $61K
15.38% more ownership
Funds ownership: 59.39% → 74.77% (+15%)
0% more funds holding
Funds holding: 62 → 62 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 18
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
68% less capital inflows, than outflows
Capital inflows: $1.96M | Capital outflows: $6.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Suvretta Capital Management
New York
|
+$766K |
| 2 |
Goldman Sachs
New York
|
+$189K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$171K |
| 4 |
Jane Street
New York
|
+$122K |
| 5 |
Prelude Capital Management
New York
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.55M |
| 2 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$1.15M |
| 3 |
Woodline Partners
San Francisco,
California
|
-$759K |
| 4 |
Atom Investors
Austin,
Texas
|
-$415K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$378K |
IRON Hedge Fund Activity: Q4 2021 in Review
62 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Disc Medicine (IRON) for Q4 2021, worth a combined $93.8M — down 9.4% from $103M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of IRON and 9 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 15 added.
The largest buyer was Suvretta Capital Management, adding an estimated $766K. The largest seller was Vanguard Group, cutting an estimated $1.55M.
- 62 institutional investors held Disc Medicine (IRON) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $93.8M of Disc Medicine stock for Q4 2021, down 9.4% quarter-over-quarter.
- 9 funds opened new Disc Medicine positions in Q4 2021 and 13 closed out, a net change of -4 holders.
- The largest Disc Medicine buyer in Q4 2021 was Suvretta Capital Management, an estimated $766K added.
- The largest Disc Medicine seller in Q4 2021 was Vanguard Group, an estimated $1.55M sold.
Based on aggregated 13F filings for Q4 2021.